Lapatinib（GW572016）对ErbB-2和EGFR酪氨酸激酶结构域具有强效抑制作用，对纯化EGFR和ErbB-2的IC50值分别为10.2 nM和9.8 nM。

Afatinib（BIBW 2992）是一种口服活性强且不可逆的ErbB家族（EGFR和HER2）双特异性抑制剂，对EGFRwt、EGFRL858R、EGFRL858R/T790M和HER2的IC50值分别为0.5 nM、0.4 nM、10 nM和14 nM。阿法替尼用于研究食管鳞状细胞癌（ESCC）、非小细胞肺癌（NSCLC）和胃癌。

Dacomitinib is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.

Allitinib tosylate（AST-1306（TsOH））是一种口服活性和不可逆的EGFR和ErbB2抑制剂，其IC50值分别为0.5和3 nM。Allitinib tosylate以0.8 nM的IC50抑制ErbB4，是一种具有抗癌活性的苯基氨基喹唑啉化合物。

TAK-285 is a dual HER2 and EGFR (HER1) inhibitor with IC50 of 17 nM and 23 nM, > 10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.

AST-1306 is an irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.

EGFR/ErbB-2/ErbB-4 inhibitor-2是一种三重靶向抑制剂，能够有效抑制 EGFR、ErbB-2 和 ErbB-4，应用于癌症治疗研究中。

Zipalertinib是一种新型的 EGFR 突变抑制剂，专门针对肿瘤中存在的特定 EGFR 突变。它在治疗各种 EGFR 突变相关癌症，如非小细胞肺癌等方面具有显著潜力。

Poziotinib is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.

AZ5104 is an irreversible inhibitor of EGFR-L858R/T790M, EGFR-L858R, EGFR-L861Q, and EGFR (IC50s of < 1 nM, 6 nM, 1 nM, and 25 nM respectively). AZ5104 is the demethylated metabolite of AZD-9291.

AEE788 is an inhibitor of both EGFR and VEGFR, the IC50s for EGFR and ErbB2 is 2 nM, 6 nM respectively.

AC480 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, > 100-fold to VEGFR2, c-Kit, Lck, MET etc.